Allergic Rhinitis
Similar to patients with asthma, the medical treatment of patients with allergic rhinitis should continue.6,7 No evidence put this category of patients at risk of severe complication; during a COVID-19 infection, not controlled allergic rhinitis in an individual with uncontrolled allergic rhinitis may increase the spread of diasease.6,7 As restrictive measures get eased allergic rhinitis patients if symptomatic may be prevented from accessing health care facilities, school, camp, and work as COVID-19 symptoms may overlap with allergic rhinitis and prescreening of symptomatic patients will be widely implemented.6,7Under red-zone circumstances, allergic rhinitis should be evaluated via telemedicine or telephone instead of in person. Evaluation for allergy can be postponed during red-zone/phase 1 restrictions. Performing skin testing or in vitro serum specific IgE testing to inhalants may be appropriate as countries go to yellow, orange zones if the risk of acquiring COVID-19 in health care facilities is low and adequate PPE protections are available to healthcare providers for the close contacts required to perform skin test.6,7
Allergen immunotherapy can be considered the following recommendation outlined before l.16